Skip to content
Other

Net cash related to derivative contracts under collateral exchange arrangements

Idexx Laboratories Net cash related to derivative contracts under collateral exchange arrangements decreased by 30.9% to $1.04M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 149.8%, from $416K to $1.04M.

Analysis

StatementIncome Statement
SectionOther
First reportedQ1 2021
Last reportedQ1 2026May 5, 2026
Metric ID: other_proceeds_from_hedge_investing_activities

Historical Data

17 periods
 Q2 '21Q3 '21Q4 '21Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0$0$0$0$0$0$6.26M$2.12M$329K$398K$415K$416K$416K$474K$349K$1.5M$1.04M
QoQ Change-66.1%-84.5%+21.0%+4.3%+0.2%+0.0%+13.9%-26.4%+330.9%-30.9%
YoY Change-93.4%-80.4%+26.4%+19.1%-15.9%+261.5%+149.8%
Range$0$6.26M
Avg YoY Growth+38.2%
Median YoY Growth+19.1%

Frequently Asked Questions

What is Idexx Laboratories's net cash related to derivative contracts under collateral exchange arrangements?
Idexx Laboratories (IDXX) reported net cash related to derivative contracts under collateral exchange arrangements of $1.04M in Q1 2026.
How has Idexx Laboratories's net cash related to derivative contracts under collateral exchange arrangements changed year-over-year?
Idexx Laboratories's net cash related to derivative contracts under collateral exchange arrangements increased by 149.8% year-over-year, from $416K to $1.04M.